Sten Nilsson

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: INVESTIGATIONAL NEW DRUGS. 2024;42(2):207-220
The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages
Henning P; Westerlund A; Moverare-Skrtic S; Lindholm C; Marquez-Mendez M; Nilsson S; Holmberg AR; Lerner UH
Article: INVESTIGATIONAL NEW DRUGS. 2023;41(5):688-698
Cytotoxicity of poly-guanidine in medulloblastoma cell lines
Gallo-Oller G; de Stahl TD; Alaiya A; Nilsson S; Holmberg AR; Marquez-Mendez M
Article: EUROPEAN JOURNAL OF CANCER. 2023;181:198-207
A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer and skeletal metastases
Thellenberg-Karlsson C; Vjaters E; Kase M; Tammela T; Ojamaa K; Norming U; Nyman C; Andersson S-O; Hublarovs O; Marquez-Holmberg M; Castellanos E; Ullen A; Holmberg A; Nilsson S
Article: TRANSLATIONAL ONCOLOGY. 2022;26:101543
Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines
Abramenkovs A; Hariri M; Spiegelberg D; Nilsson S; Stenerlow B
Article: ACTA ONCOLOGICA. 2022;61(10):1179-1185
High levels of health-related quality of life five years after curative treatment of prostate cancer with HDR-brachytherapy and external beam radiation
Hjalm-Eriksson M; Ullen A; Nilsson S; Johansson H; Nilsson J; Castellanos E; Brandberg Y
Article: ACTA ONCOLOGICA. 2021;60(10):1301-1307
High rate of local control and cure at 10 years after treatment of prostate cancer with external beam radiotherapy and high-dose-rate brachytherapy: a single centre experience
Hjalm-Eriksson M; Nilsson S; Brandberg Y; Johansson H; Lennernas B; Lundell G; Castellanos E; Ullen A
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2021;48(10):3325-3334
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
van der Doelen MJ; Stockhaus A; Ma Y; Mehra N; Yachnin J; Gerritsen WR; Nilsson S; van Oort IM; Ullen A
Article: CLINICAL GENITOURINARY CANCER. 2019;17(5):348-355.e5
Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program
Saad F; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Nilsson S; Miller K; Wirth M; Reeves J; Seger M; Carles J; Heidenreich A
Article: BMC CANCER. 2019;19(1):12
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
Article: ANTICANCER RESEARCH. 2018;38(3):1531-1537
Synthesis and Binding of a Novel PSMA-specific Conjugate
Holmberg AR; Marquez M; Lennartsson L; Meurling L; Nilsson S
Article: EUROPEAN UROLOGY. 2018;73(3):427-435
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial
Parker CC; Coleman RE; Sartor O; Vogelzang NJ; Bottomley D; Heinrich D; Helle SI; O'Sullivan JM; Fossa SD; Chodacki A; Wiechno P; Logue J; Seke M; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Kliment J; Wedel S; Boehmer S; Dall'Oglio M; Franzen L; Bruland OS; Petrenciuc O; Staudacher K; Li R; Nilsson S
Article: MOLECULAR AND CLINICAL ONCOLOGY. 2018;8(1):141-146
Effect on prostate volume following neoadjuvant treatment with an androgen receptor inhibitor monotherapy versus castration plus an androgen receptor inhibitor in prostate cancer patients intended for curative radiation therapy: A randomised study
Majumder K; Brandberg Y; Johansson H; Castellanos E; Ullen A; Lennernas B; Nilsson S
Article: CLINICAL GENITOURINARY CANCER. 2017;16(1):S1558-7673(17)30275-6-E231
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer
Heinrich D; Bektic J; Bergman AM; Caffo O; Cathomas R; Chi KN; Daugaard G; Keizman D; Kindblom J; Kramer G; Olmos D; Omlin A; Sridhar SS; Tucci M; van Oort I; Nilsson S
Article: ANNALS OF ONCOLOGY. 2017;28(5):1090-1097
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223
Sartor O; Coleman RE; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Vogelzang NJ; Bruland O; Kobina S; Wilhelm S; Xu L; Shan M; Kattan MW; Parker C
Article: CLINICAL GENITOURINARY CANCER. 2017;15(1):42-52.e8
Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial
Vogelzang NJ; Coleman RE; Michalski JM; Nilsson S; O'Sullivan JM; Parker C; Widmark A; Thuresson M; Xu L; Germino J; Sartori O
Article: ACTA ONCOLOGICA. 2017;56(1):21-26
Comorbidity as a predictor of overall survival in prostate cancer patients treated with external beam radiotherapy combined with HDR brachytherapy boosts
Hjalm-Eriksson M; Ullen A; Johansson H; Levitt S; Nilsson S; Kalkner K-M
Article: EUROPEAN JOURNAL OF CANCER. 2017;71:1-6
Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial
Parker C; Zhan L; Cislo P; Reuning-Scherer J; Vogelzang NJ; Nilsson S; Sartor O; O'Sullivan JM; Coleman RE
Article: ANTICANCER RESEARCH. 2016;36(12):6499-6504
Bone-targeted Novel Cytotoxic Polybisphosphonate Conjugate in Castration-resistant Prostate Cancer: A Multicenter Phase 1 Study
Thellenberg-Karlsson C; Nyman C; Nilsson S; Blom R; Marquez M; Castellanos E; Holmberg AR
Article: EUROPEAN UROLOGY. 2016;70(5):875-883
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial
Parker C; Finkelstein SE; Michalski JM; O'Sullivan JM; Bruland O; Vogelzang NJ; Coleman RE; Nilsson S; Sartor O; Li R; Seger MA; Bottomley D
Article: SPRINGERPLUS. 2016;5(1):1861
Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells
Ma Y; Miao Y; Peng Z; Sandgren J; De Stahl TD; Huss M; Lennartsson L; Liu Y; Nister M; Nilsson S; Li C
Visa fler

Alla övriga publikationer

Letter: EUROPEAN UROLOGY. 2019;75(3):e51-e52
The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer
O'Sullivan JM; Heinrich D; James ND; Nilsson S; Ost P; Parker CC; Tombal B
Review: PROSTATE CANCER AND PROSTATIC DISEASES. 2018;21(1):37-47
Current approaches to incorporation of radium-223 in clinical practice
Parker C; Heidenreich A; Nilsson S; Shore N
Review: SEMINARS IN NUCLEAR MEDICINE. 2016;46(6):544-556
Radium-223 Therapy of Bone Metastases in Prostate Cancer
Nilsson S
Review: CURRENT ONCOLOGY REPORTS. 2016;18(2):14
Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Nilsson S
Corrigendum: SPRINGERPLUS. 2016;5(1):2084
Erratum to: Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells.
Ma Y; Miao Y; Peng Z; Sandgren J; De Ståhl TD; Huss M; Lennartsson L; Liu Y; Nistér M; Nilsson S; Li C
Review: EXPERT OPINION ON DRUG SAFETY. 2015;14(7):1127-1136
Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety
Nilsson S
Review: AMERICAN SOCIETY OF CLINICAL ONCOLOGY EDUCATIONAL BOOK / ASCO. AMERICAN SOCIETY OF CLINICAL ONCOLOGY. MEETING. 2014;:e132-e139
Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
Nilsson S
Editorial: JOURNAL OF UROLOGY. 2013;189(6):2107-2108
Re: Early Salvage Radiation Therapy Combined with Short-Term Hormonal Therapy in Recurrent Prostate Cancer After Radical Prostatectomy: Single-Institution 4-Year Data on Outcome, Toxicity, Health-Related Quality of Life and Co-Morbidities from 184 Consecutive Patients Treated with 70 Gy
Cortes-Gonzalez JR; Castellanos E; Sandberg K; Eriksson MH; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lenneras B; Brandberg Y; Marquez M; Kalkner KM; Nilsson S
Review: EUROPEAN JOURNAL OF CANCER. 2012;48(5):678-686
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
Nilsson S; Strang P; Aksnes AK; Franzen L; Olivier P; Pecking A; Staffurth J; Vasanthan S; Andersson C; Bruland OS
Review: LAKARTIDNINGEN. 2012;109(8):412-415
[New prospects for curative radiotherapy of local advanced prostatic cancer].
Nilsson S; Castellanos E
Editorial: ACTA ONCOLOGICA. 2011;50:90-91
Introduction: Therapy with curative intent
Nilsson S; Cohn-Cedermark G; Wiklund P
Meeting abstract: EUROPEAN UROLOGY OPEN SCIENCE. 2011;10(2):335
ALKALINE PHOSPHATASE (ALP) NORMALIZATION AT 12 WEEKS AND HEMATOLOGIC PROFILE WITH REPEATED DOSING IN PATIENTS WITH BONE METASTASES FROM CASTRATION-RESISTANT PROSTATE CANCER (CRPC) TREATED WITH RADIUM-223 (ALPHARADIN™)
Parker C; O'Bryan-Tear CG; Bolstad B; Lokna A; Garcia-Vargas J; Nilsson S
Meeting abstract: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2010;78(3):S375-S376
Clinical Experience and Radiation Safety of the First-in-Class Alpha-Pharmaceutical, Alpharadin (radium-223) in Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastases
Nilsson S; Parker C; Biggin C; Bruland O
Meeting abstract: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2010;78(3):S363
Clinical Results In 1004 Patients with Localized Prostate Cancer Treated with External Beam Radiotherapy, High Dose-rate 192-iridium Brachytherapy Boost, and Neo-adjuvant Hormonal Therapy
Castellanos E; Cohn-Cedermark G; Hjelm-Eriksson M; Nilsson J; Lundell M; Lundell G; Levitt S; Kalkner K; Nilsson S
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2009;7(2):412
Alpha-emitting Radium-223: two years follow up from a randomized phase II study in patients with bone metastases from hormone refractory prostate cancer
Nilsson S; Franzen L; Parker C; Bolstad B; Ramdahl T; Thuresson M; Bruland O
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2009;7(2):409
A double-blind, randomised dose-response phase II, multicentre study of radium-223 for the palliation of painful bone metastases in castration refractory prostate cancer patients
Nilsson S; Strang P; Franzen L; Olivier P; Pecking A; Staffurth J; Vasanthan S; Andersson C; Bruland OS; Aksnes AK
Review: UROLOGY. 2008;71(6):1001-1006
Testosterone surge: Rationale for gonadotropin-releasing hormone blockers?
van Poppel H; Nilsson S
Meeting abstract: BONE. 2008;42:S108-S109
Zoledronic acid induces caspase dependent apoptosis in renal cancer cell lines
Ullen A; Lennartsson L; Kalkner K-M; Sandstroem P; Lennemaes B; Linder S; Nilsson S
Review: TUMOR BIOLOGY. 2008;29(5):311-322
Current Status of Prognostic Immunohistochemical Markers for Urothelial Bladder Cancer
Rosenblatt R; Jonmarker S; Lewensohn R; Egevad L; Sherif A; Kalkner KM; Nilsson S; Valdman A; Ullen A
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2007;5(4):295
Placebo-controlled, randomized, phase II study of radium-223 in metastatic hormone refractory prostate cancer (HRPC)
Nilsson S; Franzen L; Tyrrel C; Blom R; Tennvall J; Lennernas B; Johannessen DC; Sokal M; Parker C; Bruland OS
Visa fler

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2025-2028
Adjungerad Professor, Onkologi-Patologi, Karolinska Institutet, 1998-2010

Artiklar

Alla övriga publikationer

Anställningar

Nyheter från KI

Kalenderhändelser från KI